5.11
-0.05(-0.97%)
Currency In USD
Address
23515 NE Novelty Hill Road
Redmond, WA 98053
United States of America
Phone
425 276 2300
Website
Sector
Healthcare
Industry
Biotechnology
Employees
9
First IPO Date
August 10, 2021
| Name | Title | Pay | Year Born |
| Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc | Chief Executive Officer, President & Director | 0 | 1976 |
| Ms. Emily Pimblett | Chief Accounting Officer | 0 | 1984 |
| Ms. Jo Palmer-Phillips Ph.D. | Chief Development Officer | 0 | N/A |
| Dr. Brett Kaplan M.B.A., M.D. | Chief Operating Officer & Principal Financial Officer | 0 | 1974 |
| Dr. Nishi Rampal M.D. | Senior Vice President of Clinical Development | 0 | N/A |
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.